LAMB3 and prostate cancer: Consistent with our results, LAMC2 has been reported to be frequently co-expressed with LAMB3 in colorectal cancer, squamous cell carcinoma of the tongue [51], gastric cancer [39], prostate cancer [52] and PDAC [53], whose intracellular retention at the invasive front of cancer cells has been considered as a more invasive phenotype.